Experts are fundamentally rethinking how cognitive decline should be treated. For decades, the field focused almost exclusively on developing drugs to clear amyloid plaques from the brain—a approach that produced FDA-approved medications like lecanemab and donanemab. However, recent evidence shows that these breakthrough drugs have significant limitations: they slow cognitive decline but don’t stop it indefinitely, and they work differently in different people. This realization has shifted the entire conversation.
Rather than chasing a single pharmaceutical solution, leading researchers now argue that effective treatment requires addressing the full constellation of factors driving cognitive decline—from untreated hearing loss to air pollution exposure to social isolation. This shift represents a fundamental challenge to decades of neuroscience consensus. The amyloid hypothesis dominated research funding and drug development, yet it turns out to be only part of the story. Today’s experts are simultaneously questioning whether the drug-first approach was ever the right strategy, while discovering that nearly half of all dementia risk comes from modifiable factors that have nothing to do with amyloid plaques at all. This article explores why the current treatment paradigm is being challenged, what the alternatives look like, and what this means for people at risk of cognitive decline.
Table of Contents
- Why Amyloid-Clearing Drugs Alone Aren’t the Answer
- The Modifiable Risk Factors Experts Now Prioritize
- Precision Medicine and the Inadequacy of One-Size-Fits-All Approaches
- Non-Pharmacological Interventions Now Backed by Strong Evidence
- The Technology Frontier: 40 Hz Stimulation and Blood Biomarkers
- The Access and Equity Crisis in Cognitive Decline Treatment
- The Real Bottleneck: Healthcare Delivery, Not Drug Development
- Conclusion
Why Amyloid-Clearing Drugs Alone Aren’t the Answer
The approval of lecanemab and donanemab seemed like a landmark moment. These medications could actually remove amyloid plaques from the brain, something doctors had only dreamed of for years. Yet the clinical reality proved more complicated. While these drugs do clear amyloid effectively, they don’t prevent cognitive decline indefinitely—they slow it down for some patients, by some measures. For many people, the benefit is modest, and the requirements are strict: medications only work in early-stage disease, require regular infusions, and carry risks including amyloid-related imaging abnormalities, a concerning brain condition that can develop in treated patients. The fundamental problem is that clearing amyloid plaques doesn’t solve the underlying neurological cascade driving dementia. Experts now recognize that amyloid is one factor among many—pathological tau tangles, neuroinflammation, vascular damage, metabolic dysfunction, and neurodegeneration all play critical roles.
Focusing treatment exclusively on amyloid while ignoring these other mechanisms is like treating only high cholesterol while ignoring blood pressure in heart disease. A patient might have amyloid cleared from their brain yet still experience cognitive decline from unchecked tau pathology or chronic brain inflammation. This explains why many treated patients continue to decline cognitively despite successful amyloid removal. Additionally, access to these drugs remains severely restricted globally. Lecanemab and donanemab are available only in wealthy regions with robust healthcare systems or significant out-of-pocket resources. In many countries, they’re either unavailable or accessible only to the wealthy. This widening access gap means that a treatment hailed as a breakthrough benefits a tiny fraction of the global population at risk for cognitive decline, while hundreds of millions have no access whatsoever—raising the question of whether resources should be directed toward interventions with broader applicability.
The Modifiable Risk Factors Experts Now Prioritize
Research has firmly established that 45% of overall population dementia risk comes from modifiable factors—conditions and exposures that can actually be changed. This statistic is profound because it means nearly half of all dementia cases might be preventable through behavioral and medical interventions. The modifiable factors include midlife hypertension, low social engagement, untreated hearing loss, hyperlipidemia, obesity, physical inactivity, depression, cognitive inactivity, heavy alcohol use, and air pollution exposure. Yet many healthcare systems, research funding agencies, and pharmaceutical companies continue to pour resources into targeting the non-modifiable risk factors like genetics and amyloid pathology. However, addressing modifiable risk factors requires recognizing that they function differently across populations and individuals. Hypertension management in middle age, for example, is a proven dementia prevention strategy—but only if treatment begins before cognitive symptoms appear, and only if blood pressure remains controlled long-term.
Untreated hearing loss contributes to dementia risk because the cognitive load of straining to hear accelerates neurological aging, but hearing aids prevent this decline only if the person actually wears them consistently. This points to a crucial limitation: identifying a modifiable risk factor is only the first step. The harder work is implementing sustained behavior change and medical management across diverse populations with different access, literacy, and motivational levels. The neglect of modifiable risk factors reflects a deeper bias in medicine toward pharmaceutical interventions over lifestyle and environmental change. A drug company can develop a product, gain approval, patent it, and profit indefinitely. Hearing loss prevention through hearing aid distribution, community social programs, and air quality regulation generate no patent revenue and require sustained investment with diffuse benefits. Yet evidence increasingly shows that interventions addressing modifiable risks are not only more effective at the population level than current drugs, but also far more cost-effective and available to broader populations.
Precision Medicine and the Inadequacy of One-Size-Fits-All Approaches
The realization that amyloid-clearing drugs work differently in different people has crystallized a larger insight: there is no one-size-fits-all dementia treatment because cognitive decline is not one disease. Some people develop dementia primarily from amyloid and tau pathology (the “Alzheimer’s” pathway), while others develop it from vascular disease (small strokes and narrowed blood vessels), neurodegeneration in the frontal and temporal regions, or metabolic dysfunction. Still others develop cognitive decline from combinations of these pathologies, with different proportions in different brains. This biological diversity explains why a treatment targeting amyloid works reasonably well for some patients and barely at all for others—the patient’s actual pathology determines whether the treatment addresses their problem. Precision medicine approaches now being developed aim to identify a person’s specific cognitive decline pathway and match them to treatments targeting that pathway. This requires biomarkers—blood tests, brain imaging, or genetic markers that indicate what’s actually happening in someone’s brain. A person with predominantly amyloid pathology might benefit from amyloid-clearing drugs.
Someone with primary tau pathology would need a tau-targeting treatment. A person with vascular cognitive impairment should receive intensive vascular risk factor management, not amyloid-focused therapy. The concept seems straightforward, but implementation faces substantial obstacles: the biomarkers are expensive or not yet fully validated, identifying the right stratification strategy requires large research studies, and most primary care doctors lack training in precision medicine approaches. The current limitations are substantial. Precision medicine approaches promise better outcomes but often require access to specialists, specialized testing, and newer treatments unavailable in most healthcare settings. For the patient in a rural area seeing a general practitioner, precision medicine remains theoretical. Furthermore, even with perfect precision matching, a patient with multiple concurrent pathologies faces decisions about which pathways to target first and how to combine treatments safely. Precision medicine will likely benefit wealthy populations in wealthy countries first, exacerbating existing disparities in dementia care unless deliberate efforts are made to democratize these approaches.
Non-Pharmacological Interventions Now Backed by Strong Evidence
While pharmaceutical research dominated the field for decades, a growing body of evidence supports the effectiveness of non-pharmacological interventions for preventing and slowing cognitive decline. Physical activity, cognitive stimulation, social engagement, sleep optimization, Mediterranean-style diet adherence, and management of cardiovascular risk factors all demonstrate effects on cognitive outcomes in well-designed studies. Remarkably, many of these interventions appear as effective as current drugs for preventing cognitive decline, are far less expensive, and carry minimal risk compared to amyloid-clearing treatments. The advantage of non-pharmacological interventions extends beyond efficacy and safety. They are inherently accessible to anyone regardless of healthcare system or wealth. A person can begin a regular walking program, join a book club, or practice crossword puzzles with zero cost and no prescription requirement. Cognitive training, social engagement, and physical activity work through different mechanisms than amyloid clearance—they appear to build cognitive reserve, improve vascular function, reduce neuroinflammation, and promote neuroplasticity.
For this reason, experts increasingly view these interventions not as “alternatives” to drugs but as foundational strategies that should form the backbone of any dementia prevention program, with pharmacological treatments added only when appropriate. However, there’s a critical caveat: non-pharmacological interventions only prevent decline—they don’t reverse cognitive loss once dementia has developed. Someone with advanced Alzheimer’s disease won’t recover cognition through social programs, though engagement can improve quality of life. Additionally, sustaining these interventions long-term requires motivation, ability, and life circumstances that not everyone possesses. The person working two jobs to survive cannot easily commit to daily exercise and regular social groups. The person with severe depression may lack motivation despite knowing exercise helps. The person in poor health may be unable to engage in intensive physical activity. These interventions work, but they work best in people with sufficient resources, health, and stability to maintain them—revealing yet another equity problem in dementia care.
The Technology Frontier: 40 Hz Stimulation and Blood Biomarkers
Two emerging technologies are shifting expert thinking about what’s possible in cognitive decline treatment. The first is 40 Hz gamma wave stimulation, where flickering light or other sensory stimuli delivered at precisely 40 cycles per second appear to reduce Alzheimer’s pathology in both animal models and human studies. The mechanism appears to involve synchronizing neuronal activity and enhancing the brain’s waste clearance system. While the evidence remains early and findings are still being replicated, preliminary results suggesting reductions in amyloid, tau, and neuroinflammation have captured significant scientific attention. The second technology concerns blood biomarkers, particularly neurofilament light chain (NfL), which indicates nerve cell injury and neurodegeneration. NfL in blood can now be measured relatively inexpensively and appears to predict cognitive problems years before symptoms emerge.
This offers something the field has lacked: a way to identify cognitively normal people at imminent risk of decline, potentially enabling intervention before dementia symptoms begin. Combined with genetic markers and cognitive testing, blood biomarkers could enable true early detection, moving treatment from late-stage disease to preclinical intervention. Yet these technologies also carry limitations. The 40 Hz stimulation evidence, while promising, remains preliminary—large-scale human trials are ongoing, and optimal treatment protocols are unknown. Not every patient responds equally, and mechanisms in animal brains don’t always translate to human brains. Blood biomarkers are emerging but often require interpretation by specialists, and positive biomarker results don’t predict dementia with perfect accuracy; many cognitively normal people with biomarker evidence of pathology never develop symptoms during their lifetime. The danger is that these technologies could create a new class of “worried well”—cognitively normal people labeled as diseased based on biomarkers, subjected to preventive treatments of uncertain benefit, and burdened with the psychological weight of a disease diagnosis they don’t currently have.
The Access and Equity Crisis in Cognitive Decline Treatment
The approval of lecanemab and donanemab created an uncomfortable reality: the new breakthrough treatments are available to roughly the 20% of the world’s population living in wealthy, developed nations with healthcare systems that can absorb their costs. For everyone else—whether in middle-income countries, rural areas, or low-income regions—these drugs are simply unaffordable. Even in countries like the United States where drug access is theoretically available, insurance coverage is inconsistent, access is limited to specialized memory care centers, and even treated patients often discontinue due to logistical burden or side effects.
This access disparity means that the newest dementia treatments are functioning as a luxury good available only to the wealthy, while the proven interventions with broader applicability—blood pressure management, hearing aid distribution, cognitive stimulation, physical activity programs—remain chronically underfunded. A person in a low-income country is statistically more likely to have uncontrolled hypertension, untreated hearing loss, and social isolation—all modifiable dementia risk factors—yet has zero access to even the most basic dementia prevention programs. Meanwhile, a wealthy person can receive expensive amyloid-clearing drugs that may or may not slow their decline. This represents a profound mismatch between where the burden of dementia is heaviest and where the resources are concentrated.
The Real Bottleneck: Healthcare Delivery, Not Drug Development
As experts reassess cognitive decline treatment, a consistent finding emerges across institutions from the Salk Institute to leading academic medical centers: the bottleneck isn’t insufficient drugs. The real obstacles are healthcare delivery failures—specialist shortages, fragmented medical systems, manual paperwork, long wait times for diagnoses, and pervasive barriers to accessing evidence-based interventions. A person who needs a hearing test to prevent dementia may face a six-month wait to see an audiologist in their region. Someone who would benefit from cognitive training may find no local programs available. A patient with hypertension may never receive sustained follow-up to ensure their blood pressure stays controlled over decades.
These delivery challenges affect treatment at every level. Precision medicine requires specialty assessment unavailable in most places. Non-pharmacological interventions require community infrastructure—gym access, social programs, cognitive training resources—that exists inconsistently if at all. Even the new blood biomarkers require specialists to interpret results and guide patients through complex decision-making about whether to pursue further testing or preventive treatments. Until healthcare systems solve these delivery problems, developing new drugs provides marginal benefit to marginal populations. The future of effective cognitive decline treatment, most experts now believe, depends not on the next drug discovery but on fixing how care is organized and delivered.
Conclusion
The expert challenge to current cognitive decline treatment approaches represents a fundamental shift from pharmacology-first thinking to systems thinking. The realization that amyloid-clearing drugs have limits, that nearly half of dementia risk is modifiable, and that non-pharmacological interventions are often more effective and more accessible has forced a reckoning with decades of biomedical research priorities. Rather than waiting for the next breakthrough drug, experts increasingly emphasize what’s already known to work: managing cardiovascular risk factors from midlife onward, addressing hearing loss, maintaining cognitive and social engagement, staying physically active, and building healthcare systems capable of delivering these interventions sustainably.
For individuals concerned about cognitive decline, the implications are clear. While emerging treatments and technologies like 40 Hz stimulation and blood biomarkers may eventually play important roles, the immediate and most impactful actions remain accessible to most people: know your blood pressure and manage it if elevated, maintain hearing, stay socially engaged, exercise regularly, challenge your cognition, manage cardiovascular risk factors, and reduce exposure to air pollution where possible. These interventions won’t guarantee you’ll never develop cognitive decline—genetics and aging remain powerful forces—but they represent the most evidence-supported path forward while experts continue reshaping how cognitive decline treatment is understood and delivered.
